Status:
COMPLETED
The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients
Lead Sponsor:
Astellas Pharma Inc
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
65+ years
Brief Summary
The objective of this survey is to confirm the safety of Suglat Tablets when used in the elderly.
Detailed Description
Elderly patients (65 years or older at the time of first administration) with type 2 diabetes who used Suglat Tablets within 3 months from its launch are included in this study. Followings are measure...
Eligibility Criteria
Inclusion
- type 2 diabetes who used Suglat Tablets within 3 months from its launch
Exclusion
- off-label use patients
Key Trial Info
Start Date :
April 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2015
Estimated Enrollment :
8687 Patients enrolled
Trial Details
Trial ID
NCT02297620
Start Date
April 1 2014
End Date
July 1 2015
Last Update
October 15 2015
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Chugoku, Japan
2
Chūbu, Japan
3
Hokkaido, Japan
4
Kansai, Japan